Рыночные новости
Заголовки по акциям и крипте из Alpaca. Храним 7 дней. Всего: 9813.
-
CrowdStrike Announces 2026 European Customer Impact Award WinnersCrowdStrike recognized several customers for their leadership in AI-era security at the Fal.Con Europe 2026 conference.
-
CrowdStrike Announces Date for Fiscal Third Quarter 2027 Financial ResultsCrowdStrike has scheduled its fiscal third quarter 2027 financial results conference call.
-
BlackRock Greater Europe Investment Trust Issues New SharesBlackRock Greater Europe Investment Trust plc issued 6,000 new shares at £5.5421 per share in connection with a scheme of reconstruction involving BlackRock Throgmorton Trust plc.
-
Fresh Step Fleur de Purr Launches Exclusively at Walmart.comFresh Step has introduced its new Fleur de Purr cat litter, available exclusively on Walmart.com starting November 4, 2026.
-
Coaqua Launches Nationwide at WalmartCoaqua has launched its premium coconut water across more than 3,000 Walmart stores nationwide.
-
BlackRock's iShares Bitcoin Trust Records $95 Million OutflowBlackRock's iShares Bitcoin Trust (IBIT) experienced a $95 million net outflow on November 3, 2026, as part of a broader three-day withdrawal trend across spot Bitcoin ETFs.
-
Merck Updates 2026 Financial GuidanceMerck & Co., Inc. has revised its full-year 2026 financial outlook, increasing its worldwide sales and non-GAAP EPS guidance.
-
Peer-Reviewed Study Published in HCA Healthcare Journal of MedicineA new peer-reviewed study has been published in the HCA Healthcare Journal of Medicine regarding Phase 2 research.
-
FDA Grants Emergency Use Authorization for Merck's BravectoThe U.S. Food and Drug Administration has issued an emergency use authorization for Merck's Bravecto to treat screwworm infestations in dogs.
-
Barclays Raises Vertex Pharmaceuticals Price Target to $626Barclays has increased its price target for Vertex Pharmaceuticals Incorporated from $617 to $626.
-
Polaris Rx Selected to Dispense Bristol Myers Squibb's ZENBEXUS™Bristol Myers Squibb has selected Polaris Rx as a specialty pharmacy provider for ZENBEXUS™ (iberdomide), its recently FDA-approved therapy for multiple myeloma.
-
Bristol Myers Squibb Canada Launches Melanoma Awareness CampaignBristol Myers Squibb Canada has launched "What Summer Leaves Behind," a public awareness campaign designed to help identify the warning signs of melanoma and other skin cancers.
-
Mahoney Environmental Reports Success in Grease Theft Prevention ProgramNeste subsidiary Mahoney Environmental announced that its Grease Theft Rewards Program and specialized team supported four recent incidents, leading to nine arrests in under a month.
-
Hotwire Communications Selects Nokia for Network Deployment in North CarolinaNokia announced it has been chosen by Hotwire Communications to deploy a next-generation network in North Carolina.
-
Ichnos Glenmark Innovation to Present Updated Clinical Data for ABBV-2001Ichnos Glenmark Innovation will present updated Phase 1 clinical data for the trispecific T-cell engager ISB 2001, developed in partnership with AbbVie, at the ASH Annual Meeting.
-
Genmab and AbbVie to Present Epcoritamab Data at ASH Annual MeetingGenmab and AbbVie will present 22 abstracts, including Phase 3 data for epcoritamab, at the 68th American Society of Hematology Annual Meeting.
-
ExxonMobil to Participate in Asopos-1 Offshore Drilling in GreeceExxonMobil is part of a consortium led by Energean for the upcoming Asopos-1 exploratory drilling project in Greece's Block 2, scheduled for April 2027.
-
ModelOp Integrates AI Governance with NVIDIA OpenShellModelOp has announced a new integration with NVIDIA OpenShell, enabling centralized AI policy enforcement at the operating system level.
-
Analysts Adjust Price Targets for AMETEK Following Q3 2026 EarningsSeveral financial institutions, including RBC, BMO Capital, and Citigroup, updated their price targets for AMETEK, Inc. on November 4, 2026, following the company's third-quarter earnings report.
-
Moderna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 ASH Annual MeetingModerna announced that initial clinical data from its Phase 1/2 MyEngage trial of mRNA-2808 for relapsed or refractory multiple myeloma will be presented at the 68th American Society of Hematology Annual Meeting.